Price disparities for top product Lantus Solostar - U.S. and international 2017

Price disparities for top pharmaceutical product Lantus Solostar in the U.S. and Canada as of 2017 (in U.S. dollarsl)*

by Matej Mikulic, last edited Jan 7, 2019
Price disparities for top product Lantus Solostar - U.S. and international 2017 This statistic displays price disparities for Sanofi's pharmaceutical product Lantus Solostar as of Q2 2017. For this time, Lantus Solostar cost 1160.39 U.S. dollars for a three-month supply in the U.S. while the same drug was available for 447 U.S. dollars in Canada.
Show more

Price disparities for top pharmaceutical product Lantus Solostar in the U.S. and Canada as of 2017 (in U.S. dollarsl)*

You need to log in to download this statistic
Register for free
Already a member?
Log in
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Pharmaceutical trends in Europe"
  • Overview
The most important statistics
  • European Pharmaceutical companies
  • Self-medication market
  • Employment
  • Clinical Trials
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.